Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Lixisenatide

    Client Email Product

    Lixisenatide

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Related ProductsRelated Products
    API SUPPLIERS
    API Suppliers

    API Suppliers

    5
    US DMFs Filed

    US DMFs Filed

    0

    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    5
    API REF. PRICE (USD / KG)

    0

    API Market Place

    1
    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    3
    Europe

    Europe

    9
    Canada

    Canada

    1
    Australia

    Australia

    0

    South Africa

    South Africa

    4
    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    0

    Annual Reports

    0

    FDF Market Place

    0

    EXCIPIENTS
    5
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    3

    News

    40
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    1
    SERVICES

    0

    Full View ScreenFull Screen View
    UK probes GLP-1 drugs' potential suicide risks
    UK probes GLP-1 drugs' potential suicide risks

    https://www.fiercepharma.com/pharma/glp-1-drugs-novo-az-lilly-and-sanofi-under-uk-probe-over-their-suicide-risks-reuters

    Angus Liu FIERCE PHARMA
    27 Jul 2023
    Share Share
    Sanofi Ave Soliqua Insulin Glargine:Lixisenatide Receives Approval in the U.S.
    Sanofi Ave Soliqua Insulin Glargine:Lixisenatide Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208673

    FDA
    10 Jun 2022
    Share Share
    Sanofi Aventis Adlyxin (Lixisenatide) Receives Approval in the U.S.
    Sanofi Aventis Adlyxin (Lixisenatide) Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208471

    FDA
    10 Jun 2022
    Share Share
    SMC recommends Suliqua for restricted use in combination with metformin
    SMC recommends Suliqua for restricted use in combination with metformin

    https://www.pharmiweb.com/press-release/2020-04-16/smc-recommends-suliqua-insulin-glarginelixisenatide-for-restricted-use-in-combination-with-metformin-for-the-treatment-of-adults-with-type-2-diab

    PHARMIWEB
    16 Apr 2020
    Share Share
    Sanofi talks up personalized diabetes care in patient-centric awareness push
    Sanofi talks up personalized diabetes care in patient-centric awareness push

    https://www.fiercepharma.com/marketing/sanofi-launches-diabetes-campaign-to-advance-personalized-patient-approach

    Beth Snyder Bulik FIERCE PHARMA
    10 Jun 2019
    Share Share
    US FDA approves expanded use of Soliqua 100/33
    US FDA approves expanded use of Soliqua 100/33

    http://www.pharmabiz.com/NewsDetails.aspx?aid=114395&sid=2

    PHARMABIZ
    28 Feb 2019
    Share Share
    Sanofi-Aventis’s Suliqua (insulin glargine/lixisenatide) Receives Approval In Europe
    Sanofi-Aventis’s Suliqua (insulin glargine/lixisenatide) Receives Approval In Europe

    https://www.pharmacompass.com/pdf/news/sanofi-aventiss-suliqua-insulin-glarginelixisenatide-receives-approval-in-europe-1490962039.pdf

    EMA
    30 Mar 2017
    Share Share
    Tetraphase antibiotic may reach up to $700 million in annual sales: CEO
    Tetraphase antibiotic may reach up to $700 million in annual sales: CEO

    http://www.reuters.com/article/us-tetraphase-outlook-ceo-idUSKBN15O157

    Bill Berkrot  REUTERS
    09 Feb 2017
    Share Share
    EU approval for Sanofi’s diabetes combo
    EU approval for Sanofi’s diabetes combo

    http://www.pharmatimes.com/news/eu_approval_for_sanofis_diabetes_combo_1184525

    Selina McKee PHARMATIMES
    18 Jan 2017
    Share Share
    EU approval of Suliqua(TM) triggers USD 10 million milestone payment to Zealand
    EU approval of Suliqua(TM) triggers USD 10 million milestone payment to Zealand

    https://globenewswire.com/news-release/2017/01/17/906433/0/en/EU-approval-of-Suliqua-TM-triggers-USD-10-million-milestone-payment-to-Zealand.html

    GLOBENEWSWIRE
    17 Jan 2017
    Share Share
    Sanofi beats Novo to launch with diabetes combo Soliqua
    Sanofi beats Novo to launch with diabetes combo Soliqua

    http://www.fiercepharma.com/marketing/sanofi-beats-novo-to-launch-diabetes-combo-soliqua-kicking-off-market-share-grab

     Carly Helfand  FIERCE PHARMA
    06 Jan 2017
    Share Share
    Platypus venom could give rise to a new class of diabetes treatments
    Platypus venom could give rise to a new class of diabetes treatments

    http://www.fiercebiotech.com/research/platypus-venom-could-give-rise-to-a-new-class-diabetes-treatments

    Amirah Al Idrus FIERCE BIOTECH
    30 Nov 2016
    Share Share
    Novo, Sanofi go head to head as FDA clears new diabetes drugs
    Novo, Sanofi go head to head as FDA clears new diabetes drugs

    https://www.japantoday.com/category/health/view/novo-sanofi-go-head-to-head-as-fda-clears-new-diabetes-drugs

    JAPAN TODAY
    24 Nov 2016
    Share Share
    USFDA Approves Soliqua 100/33 for the Treatment of Adults with Type 2 Diabetes
    USFDA Approves Soliqua 100/33 for the Treatment of Adults with Type 2 Diabetes

    https://globenewswire.com/news-release/2016/11/22/891888/0/en/The-U-S-FDA-approves-Soliqua-TM-100-33-for-the-treatment-of-adults-with-type-2-diabetes.html

    GLOBENEWSWIRE
    22 Nov 2016
    Share Share
    FDA Approves Sanofi's Combination Diabetes Drug
    FDA Approves Sanofi's Combination Diabetes Drug

    http://www.dddmag.com/news/2016/11/fda-approves-sanofis-combination-diabetes-drug?

    DDDMAG
    22 Nov 2016
    Share Share
    Sanofi's Soliqua Receives Approval In US
    Sanofi's Soliqua Receives Approval In US

    http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208673

    FDA
    21 Nov 2016
    Share Share
    Nine Therapies Put Forward for EU Approval
    Nine Therapies Put Forward for EU Approval

    http://www.pharmatimes.com/news/nine_therapies_put_forward_for_eu_approval_1176576

    Selina McKee PHARMATIMES
    15 Nov 2016
    Share Share
    CHMP issues positive opinion recommending Suliqua for approval in the EU
    CHMP issues positive opinion recommending Suliqua for approval in the EU

    https://globenewswire.com/news-release/2016/11/11/889230/0/en/CHMP-issues-positive-opinion-recommending-Suliqua-TM-iGlarLixi-for-approval-in-the-EU.html

    GLOBENEWSWIRE
    11 Nov 2016
    Share Share
    Sanofi provides update on NDA for daily FDC of insulin glargine & lixisenatide
    Sanofi provides update on NDA for daily FDC of insulin glargine & lixisenatide

    http://www.pharmabiz.com/NewsDetails.aspx?aid=97026&sid=2

    PHARMABIZ
    22 Aug 2016
    Share Share
    Sanofi loses lead on diabetes combo IGlarLixi after FDA delay
    Sanofi loses lead on diabetes combo IGlarLixi after FDA delay

    http://www.pmlive.com/pharma_news/sanofi_loses_its_lead_on_diabetes_combo_iglarlixi_after_fda_delay_1106791

    Phil Taylor PMLIVE
    22 Aug 2016
    Share Share
    Sanofi Receives FDA Approval of Adlyxin™ for Treatment of Type 2 Diabetes
    Sanofi Receives FDA Approval of Adlyxin™ for Treatment of Type 2 Diabetes

    http://www.prnewswire.com/news-releases/sanofi-receives-fda-approval-of-adlyxintm-for-treatment-of-adults-with-type-2-diabetes-300305253.html

    PR NEWSWIRE
    27 Jul 2016
    Share Share
    IDegLira receives unanimous 16-0 vote in favor of approval from FDA Advisory Committee
    IDegLira receives unanimous 16-0 vote in favor of approval from FDA Advisory Committee

    https://globenewswire.com/news-release/2016/05/24/843002/0/en/IDegLira-receives-positive-16-0-vote-in-favour-of-approval-from-FDA-Advisory-Committee.html

    GLOBAL NEWS WIRE
    25 May 2016
    Share Share
    New T2D Drugs Face Skeptical FDA Advisors
    New T2D Drugs Face Skeptical FDA Advisors

    http://www.medpagetoday.com/PublicHealthPolicy/FDAGeneral/58091?xid=nl_mpt_DHE_2016-05-24&eun=g655567d0r

    Parker Brown MEDPAGE TODAY
    24 May 2016
    Share Share
    FDA Accepts Sanofi NDA for Combination of Insulin Glargine and Lixisenatide
    FDA Accepts Sanofi NDA for Combination of Insulin Glargine and Lixisenatide

    http://www.prnewswire.com/news-releases/fda-accepts-sanofi-new-drug-application-for-once-daily-fixed-ratio-combination-of-insulin-glargine-and-lixisenatide-300223605.html

    PR NEWSWIRE
    23 Feb 2016
    Share Share
    Sanofi Announces Soliqua 100/33 Now Available in the U.S.
    Sanofi Announces Soliqua 100/33 Now Available in the U.S.

    http://www.dddmag.com/news/2017/01/sanofi-announces-soliqua-100-33-now-available-us

    DDDMAG
    10 Jan 2016
    Share Share
    Sanofi Seeks FDA Approval for Diabetes Drug Combination
    Sanofi Seeks FDA Approval for Diabetes Drug Combination

    http://www.nasdaq.com/article/sanofi-seeks-fda-approval-for-diabetes-drug-combination-cm559323?

    NASDAQ
    28 Dec 2015
    Share Share
    Sanofi uses priority review voucher for diabetes combo
    Sanofi uses priority review voucher for diabetes combo

    http://www.pmlive.com/pharma_news/sanofi_uses_priority_review_voucher_for_diabetes_combo_892281

    Phil Taylor PM LIVE
    26 Dec 2015
    Share Share
    Sanofi takes an FDA shortcut with its diabetes combo, racing with Novo
    Sanofi takes an FDA shortcut with its diabetes combo, racing with Novo

    http://www.fiercebiotech.com/story/sanofi-takes-fda-shortcut-its-diabetes-combo-racing-novo/2015-12-23

    Damian Garde FIERCE BIOTECH
    24 Dec 2015
    Share Share
    Sanofi submits new diabetes drug application to U.S. regulator
    Sanofi submits new diabetes drug application to U.S. regulator

    http://www.reuters.com/article/us-sanofi-diabetes-us-idUSKBN0U60I920151223

    James Regan REUTERS
    22 Dec 2015
    Share Share
    Lyxumia's may help Sanofi's case for approval,but won't score against SGLT2s
    Lyxumia's may help Sanofi's case for approval,but won't score against SGLT2s

    http://www.fiercepharma.com/story/lyxumias-cv-results-may-help-sanofis-case-approval-they-wont-score-it-point/2015-12-03

    Carly Helfand FIERCE PHARMA
    03 Dec 2015
    Share Share
    Sanofi's back-to-growth strategy fails to impress analysts
    Sanofi's back-to-growth strategy fails to impress analysts

    http://www.fiercepharma.com/story/sanofis-back-growth-strategy-fails-impress-analysts/2015-11-09

    Tracy Staton FIERCE PHARMA
    10 Nov 2015
    Share Share
    Sanofi Files U.S. Drug Application for Lixisenatide
    Sanofi Files U.S. Drug Application for Lixisenatide

    http://www.nasdaq.com/article/sanofi-files-us-drug-application-for-lixisenatide-20150929-00031?

    NASDAQ
    28 Sep 2015
    Share Share
    Zealand Pharma gains 20% after PhIII success clears path to diabetes payday
    Zealand Pharma gains 20% after PhIII success clears path to diabetes payday

    http://www.fiercebiotech.com/story/zealand-pharma-gains-20-after-phiii-success-clears-path-diabetes-payday/2015-09-17

    Nick Paul Taylor FIERCE BIOTECH
    17 Sep 2015
    Share Share
    Victoza tops Sanofi's Lyxumia in trial, adding to Novo's GLP-1 arsenal
    Victoza tops Sanofi's Lyxumia in trial, adding to Novo's GLP-1 arsenal

    http://www.fiercepharma.com/story/victoza-tops-sanofis-lyxumia-trial-adding-novos-glp-1-arsenal/2015-09-16

    Tracy Staton FIERCE PHARMA
    16 Sep 2015
    Share Share
    No change in CV risk for ACS patients on Sanofi's Lyxumia
    No change in CV risk for ACS patients on Sanofi's Lyxumia

    http://www.fiercepharma.com/story/no-change-cv-risk-acs-patients-sanofis-lyxumia/2015-08-31

    Carly Helfand FIERCE PHARMA
    31 Aug 2015
    Share Share
    Sanofi's Lixilan Hits Phase III Goal
    Sanofi's Lixilan Hits Phase III Goal

    http://www.biospace.com/News/sanofis-lixilan-hits-phase-iii-goal/385941/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews

    BIOSPACE
    29 Jul 2015
    Share Share
    Sanofi's combination diabetes drug hits goal in late-stage trial
    Sanofi's combination diabetes drug hits goal in late-stage trial

    http://www.reuters.com/article/2015/07/29/us-sanofi-diabetes-idUSKCN0Q30BW20150729

    REUTERS
    28 Jul 2015
    Share Share
    Sanofi will resubmit Lyxumia for FDA approval in Q3
    Sanofi will resubmit Lyxumia for FDA approval in Q3

    http://www.pmlive.com/pharma_news/sanofi_will_resubmit_lyxumia_for_fda_approval_in_q3_753031

    Dominic Tyer PM LIVE
    10 Jun 2015
    Share Share
    FDA staff question utility, trials of Novo Nordisk diabetes drug
    FDA staff question utility, trials of Novo Nordisk diabetes drug

    http://www.reuters.com/article/us-novo-nordisk-diabetes-fda-idUSKCN0YB1ID

    Toni Clarke REUTERS
    21 May 2015
    Share Share
    Sanofi's Diabetes Franchise One Step Closer To U.S. Lyxumia Launch
    Sanofi's Diabetes Franchise One Step Closer To U.S. Lyxumia Launch

    http://www.fiercepharma.com/story/sanofis-diabetes-franchise-one-step-closer-us-lyxumia-launch/2015-03-19

    Tracy Staton FIERCE PHARMA
    20 Mar 2015
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search